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CHRONIC OBSTRUCTIVE PULMONARY DISEASE
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Background: Quadriceps muscle weakness is common in chronic obstructive pulmonary disease (COPD)
but is not observed in a small hand muscle (adductor pollicis). Although this could be explained by reduced
activity in the quadriceps, the observation could also be explained by anatomical location of the muscle or
fibre type composition. However, the abdominal muscles are of a similar anatomical and fibre type
distribution to the quadriceps, although they remain active in COPD. Cough gastric pressure is a recently
described technique that assesses abdominal muscle (and hence expiratory muscle) strength more
accurately than traditional techniques. A study was undertaken to test the hypothesis that more severe
weakness exists in the quadriceps than in the abdominal muscles of patients with COPD compared with
healthy elderly controls.
Methods: Maximum cough gastric pressure and quadriceps isometric strength were measured in 43
patients with stable COPD and 25 healthy elderly volunteers matched for anthropometric variables.
Results: Despite a significant reduction in mean quadriceps strength (29.9 kg v 41.2 kg; 95% CI 217.9 to
24.6; p = 0.001), cough gastric pressure was preserved in patients with COPD (227.3 cm H2O v
204.8 cm H2O; 95% CI 25.4 to 50.6; p = 0.11).
Conclusions: Abdominal muscle strength is preserved in stable COPD outpatients in the presence of
quadriceps weakness. This suggests that anatomical location and fibre type cannot explain quadriceps
weakness in COPD. By inference, we conclude that disuse and consequent deconditioning are important
factors in the development of quadriceps muscle weakness in COPD patients, or that activity protects the
abdominal muscles from possible systemic myopathic processes.
A
lthough skeletal muscle dysfunction is well recognised
in chronic obstructive pulmonary disease (COPD),1
most research has concentrated on the quadriceps
because it is a primary locomotor muscle and readily
accessible. Controversy remains as to whether the mechan-
isms of skeletal muscle dysfunction are local, systemic, or
both. A predominantly systemic process would result in a
widely distributed loss of muscle function, whereas chronic
inactivity as a result of breathlessness and subsequent
deconditioning would result in dysfunction predominantly
in the locomotor muscles such as the quadriceps. We have
previously shown that, in stable non-weight losing patients
with COPD, adductor pollicis strength is preserved despite
significant weakness in the quadriceps.2 Although this would
suggest that inactivity (and subsequent disuse atrophy) is the
dominant aetiology, it is possible that a systemic process may
have a predilection for certain muscle fibre types. Whereas
the adductor pollicis is composed principally of type I fibres,
the quadriceps consists of 43% type I fibres and 57% type II
fibres.3 Similarly, the adductor pollicis is located distally
while the quadriceps is a proximal muscle. Some myopathic
processes such as steroid myopathy are known to preferen-
tially affect proximal musculature.4
The expiratory muscles, of which the most important are
those of the anterior abdominal wall, are proximally located
and have a similar muscle fibre type distribution to the
quadriceps.3 However, whereas the quadriceps muscle is
chronically underused, the abdominal muscles contract
during coughing (a frequent symptom in COPD) and are
recruited during exercise,5 and may often be active at rest.6
Hence, evidence of abdominal muscle weakness in conjunc-
tion with quadriceps weakness would support the hypothesis
that systemic factors are important in causing weakness,
whereas preserved abdominal muscle strength would by
inference support the notion that reduced use is a necessary
condition for the development of quadriceps weakness.
Several previous studies have measured expiratory muscle
strength in COPD,7–17 but there is no consensus over whether
weakness is present, and few have simultaneously measured
quadriceps strength. The differences between studies may
reflect patient selection and the matching of appropriate
control groups. The choice of test to assess expiratory muscle
strength and familiarity of subjects with the test may also be
relevant.
In past studies maximum expiratory mouth pressure
(PEmax) has been used to assess expiratory muscle strength.
This well established, non-invasive, and reproducible man-
oeuvre excludes expiratory muscle weakness when normal
values are obtained, but care is needed when interpreting low
values. In the evaluation of expiratory muscle weakness,
PEmax has a positive predictive value of only 58%.18 A
recently introduced test involving measurement of cough
gastric pressure is a more natural manoeuvre which is easier
for patients to perform and has a higher positive predictive
value (94%) in detecting abdominal (and hence expiratory)
muscle weakness.18
To clarify whether expiratory muscle strength is preserved
or reduced in the presence of quadriceps weakness, we
measured cough gastric pressure and quadriceps maximum
voluntary contraction force in a group of COPD patients and
age matched healthy controls. Data obtained from some of
the healthy elderly controls contributed to the normal values
Abbreviations: BMI, body mass index; COPD, chronic obstructive
pulmonary disease; cough Pga, cough gastric pressure; FEV1, forced
expiratory volume in 1 second; FFM, fat free mass; FFMI, fat free mass
index; PEmax, maximum expiratory mouth pressure; QMVC, quadriceps
maximum voluntary contraction; TLC, total lung capacity
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of cough gastric pressure reported in a previous study,18 and
data obtained from some of the COPD patients contributed to
baseline measurements reported in previous studies.19 20
METHODS
Forty three stable patients with COPD referred to a
pulmonary rehabilitation programme, with no infective
exacerbation in the preceding 4 weeks, were recruited to
the study. All had a smoking history of at least 20 pack-years
with a clinical course consistent with the British Thoracic
Society criteria for diagnosis,21 and complained of significant
functional limitation due to dyspnoea. Twenty five healthy
active elderly volunteers with no history of respiratory disease
were also recruited. Study participants were free from co-
morbidities that could limit mobility or reduce muscle
strength. The local research ethics committee of King’s
College Hospital approved the study and all participants gave
informed consent.
Expiratory muscle strength was assessed in each partici-
pant by recording the cough gastric pressure (cough Pga).
Quadriceps muscle strength was measured by recording the
isometric quadriceps maximum voluntary contraction of the
dominant leg. Fat free mass (FFM) was estimated using
bioelectrical impedance analysis and disease and age specific
regression equations.22 23 FFM was normalised to height by
calculating the fat free mass index (FFMI = FFM (kg)/
height (m)2). Spirometric parameters and lung volumes
obtained from body plethysmography were measured in the
COPD patients.
Cough Pga was measured as previously described18 using a
balloon catheter passed nasally following local anaesthesia of
the nasal mucosa and pharynx. The tip of the balloon was
placed 70 cm from the nostril and correct placement in the
stomach was confirmed by a positive deflection during a sniff
manoeuvre. Seated subjects were asked to perform maximal
single coughs at 30 second intervals until no further increase
in cough Pga was observed. The investigator gave verbal
encouragement throughout the study and cough Pga
manoeuvres were displayed on a computer screen to provide
visual feedback for the subject.
Isometric quadriceps maximum voluntary contraction
(QMVC) was studied using the technique previously
described by Polkey and colleagues24 with a specially
designed chair from which the back was removed and laid
flat. All subjects were studied supine or semi-supine (based
on subject comfort), keeping the knee flexed at 90˚over the
end of the chair. An inextensible strap was placed around the
ankle and connected to a strain gauge, mounted to the back
of the chair so that the strap ran perpendicular to the ankle
and gauge. A restraining belt was used to fix the pelvis and
lower trunk to minimise unwanted movement. Subjects were
asked to extend their knee maximally against the strap.
Consecutive efforts were made at 30 second intervals, with
visual feedback and verbal encouragement from the investi-
gator, until no further increase in QMVC occurred.
Data analysis
Statistical analysis was performed using SPSS Version 11.5
for Windows. As data were normally distributed, differences
between the COPD and control groups were compared using
unpaired t tests.
RESULTS
Anthropometric data for the COPD patients (n=43) and
healthy elderly control subjects (n=25) are summarised in
table 1. The two groups were well matched for sex, height,
weight, BMI, FFM, and FFMI. Twenty five of the COPD
patients had received oral prednisolone in the preceding year
with a mean daily dose of 3.26 mg (four were on
maintenance oral corticosteroids and 21 had received
corticosteroid burst regimens for an infective exacerbation).
Table 1 Anthropometric and lung function measurements in study participants
Healthy elderly
control group COPD group
Mean difference
(95% CI) p value
Sex (M/F) 16/9 30/13 – 0.62*
Age (years) 67.6 (14.1) 64.6 (10.1) 23.0 (28.9 to 2.9) 0.31
Height (m) 1.69 (0.10) 1.68 (0.08) 20.01 (20.06 to 0.03) 0.58
Weight (kg) 74.3 (13.1) 69.0 (16.1) 25.3 (212.9 to 2.2) 0.16
BMI (kg/m2) 25.8 (3.0) 24.5 (5.8) 21.3 (23.8 to 1.2) 0.29
FFM (kg) 50.3 (12.6) 46.7 (7.0) 23.6 (28.4 to 1.1) 0.13
FFMI (kg/m2) 17.3 (2.6) 16.5 (2.2) 20.8 (21.9 to 0.4) 0.20
FEV1 (% predicted) – 35.4 (18.2) – –
TLC (% predicted) – 125 (20) – –
Data expressed as mean (SD) or mean difference (95% confidence interval).
BMI, body mass index; FFM, fat free mass; FFMI, fat free mass index; FEV1, forced expiratory volume in 1 second;
TLC, total lung capacity.










































Figure 1 Scatterplots showing individual data and group means of
expiratory muscle and quadriceps strength in healthy elderly controls
and patients with chronic obstructive pulmonary disease (COPD). Cough
Pga, cough gastric pressure; quadriceps MVC, isometric quadriceps
maximum voluntary contraction.
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Seven patients were receiving domiciliary long term oxygen
therapy. Nutritional depletion was considered to be present if
FFMI was ,15 for women or ,16 for men.22 Based on these
criteria, 15 of the 43 patients were nutritionally depleted.
Figure 1 shows individual data and group means for cough
Pga and QMVC. Mean (SD) QMVC was reduced in patients
with COPD (29.9 (13.2) kg) compared with the control group
(41.2 (13.3) kg; 95% CI 217.9 to 24.6; p=0.001). When
stratified for sex, QMVC remained significantly reduced in
both male and female COPD patients compared with their
healthy counterparts (female: 23.2 (10.2) kg v 29.6 (6.0) kg,
p=0.03; male: 32.8 (13.4) kg v 47.7 (11.8) kg, p=0.0006).
There was a trend for cough Pga to be increased in the COPD
group, although this did not reach statistical significance
(227.3 (54.2) cm H2O v 204.8 (58.3) cm H2O; 95% CI 25.4 to
50.6; p=0.11). This was not affected by stratification for sex
(female: 197.5 (50.4) kg v 167.0 (44.3) kg, p=0.16; male:
240.3 (51.2) kg v 226.0 (55.4) kg, p=0.39).
There was no linear relationship between FFMI and either
QMVC (r2,0.01; p=0.53) or cough Pga (r2=0.02; p=0.41)
in the COPD patients. No significant relationship was found
between percentage predicted total lung capacity (TLC) and
cough Pga (r2,0.001; p=0.85).
DISCUSSION
The principal finding of this study is that cough Pga is normal
in COPD patients compared with healthy elderly controls
matched for age and FFM, despite a substantial reduction in
quadriceps strength. These data support the hypothesis that a
systemic process alone is not responsible for quadriceps
weakness in non-weight losing patients with COPD. Before
enlarging on these points, it is appropriate to discuss the
methodology.
Cough Pga as an index of expiratory muscle strength
In this study cough Pga was used as an index of expiratory
muscle strength rather than the more traditional maximum
expiratory mouth pressure (PEmax). PEmax is the only
commonly used test for assessment of expiratory muscle
strength and has many advantages. It is non-invasive,
reproducible, and normal values are well described. When
high values of PEmax are obtained, expiratory muscle
weakness can be excluded.18 However, care is required in
interpreting low values as many subjects may underperform
this manoeuvre. In a recent study of 293 patients referred for
respiratory muscle testing, over 40% of patients with a low
PEmax had a normal cough Pga,18 demonstrating that PEmax
commonly underestimates true expiratory muscle strength.
Measurement of cough Pga offers an alternative to PEmax as
the principal expiratory muscles—the abdominal muscles—
are strongly recruited in cough. While it is not a non-
volitional technique, it has the advantage that, as a natural
dynamic manoeuvre, cough is technically easier to perform
than PEmax while retaining similar between occasion
reproducibility.18 The obvious disadvantage of the technique
is that it is invasive, requiring the placement of a balloon
catheter. However, in this clinical research study all
participants tolerated the procedure well and there were no
adverse events. The expiratory muscles, like the quadriceps,
can be assessed non-volitionally by magnetic stimulation of
the lower thoracic nerve roots.25 However, this technique,
unlike stimulation of the femoral nerve or phrenic nerves, is
not supramaximal and hence is less useful when precisely
quantifying expiratory muscle strength.
A possible confounding factor is increased lung volume
and the effect on the length-tension relationship of the
abdominal muscles. Cough Pga measurements were per-
formed at or near TLC, and one would expect the patients
with COPD, with their increased TLC, to produce higher
gastric pressures during the manoeuvres. However, previous
studies from our laboratory have shown that lung volume
exerts only a relatively modest effect on Pga.26 27 Using paired
magnetic stimuli of the thoracic nerve roots, Pga only
increases about 17% from functional residual capacity to
TLC.26 In this study no significant relationship was found
between TLC and cough Pga.
Patient selection
The patients recruited for this study were sedentary, clinically
stable patients with moderate to severe COPD, as commonly
seen in respiratory outpatient clinics. Mean forced expiratory
volume in 1 second (FEV1) was 35% predicted (range 12–
58%), and all had been referred to a pulmonary rehabilitation
programme. Although the BMI, FFM, and FFMI of the
patients were not significantly lower than the control group,
35% of the patients met standard criteria for nutritional
depletion, supporting previous observations of body composi-
tion in patients with stable COPD.28 A limitation of our study
is that we did not make formal objective measurements of
daily activity levels. However, we believe it is reasonable to
assume our patients were more sedentary than their healthy
counterparts.29 All patients complained of exertional dys-
pnoea and reduced exercise tolerance (hence their referral to
pulmonary rehabilitation), while all the healthy elderly
controls were either in part or full time employment or led
active social lives.
Previous studies of expiratory muscle strength in
COPD
Several previous studies have measured expiratory muscle
strength in COPD,7–17 but no consensus has been reached over
whether weakness is present. Some investigators have
described significant expiratory muscle weakness,8–10 13–16
whereas others have shown normal strength11 17 or, indeed,
increased strength.7 These differences may be due to patient
selection, the absence of appropriate healthy control groups,
or differences in nutritional status. An alternative explana-
tion may in part be the choice of PEmax as the test of
expiratory muscle strength, and this study is novel in that it
is the first to measure cough Pga in both COPD patients and
healthy controls. Only one other study has used the cough
manoeuvre to measure expiratory muscle strength in COPD.
In 1968 Byrd and Hyatt measured cough oesophageal
pressures in 31 patients with chronic obstructive lung
disease7 and showed, as in our study, higher cough pressures
than corresponding mouth static pressures, although no
measurements in controls were made nor measurements of
quadriceps strength in the patients.
Few studies have directly compared the expiratory muscles
with the quadriceps muscle in patients with COPD. Gosselink
and colleagues measured respiratory muscle, handgrip, and
quadriceps strength as well as exercise capacity in 41 patients
with COPD and found similar reductions in PEmax and
isometric quadriceps force.9 However, FFM measurements
were not made and the muscle strength data were compared
with historical normal values. The same group later
quantified respiratory and peripheral muscle strength in 40
COPD patients and 22 healthy elderly controls.10 Although
they concluded that muscle weakness did not affect all
muscles to a similar extent, the reduction in strength in the
expiratory muscles was similar to the reduction seen in knee
extension. However, their patients were not matched to the
controls in terms of weight or BMI, hence the influence of
nutritional status and FFM as confounding factors on
expiratory muscle strength could not be excluded. In
contrast, the patients in the current study had normal cough
Pga values but significantly reduced quadriceps maximum
720 Man, Hopkinson, Harraf, et al
www.thoraxjnl.com
 on 30 June 2008 thorax.bmj.comDownloaded from 
voluntary contraction force compared with controls matched
for FFM.
Significance of findings
In the present study it was observed that cough Pga in the
COPD group was preserved compared with pressures
obtained from a group of healthy active elderly subjects
matched for age, sex, and anthropometric values, despite a
significant reduction in quadriceps strength. This supports
the hypothesis that local rather than systemic factors have a
principal role in initiating muscle dysfunction. An obvious
local factor is inactivity and subsequent muscle decondition-
ing due to the sedentary lifestyles of patients locked in a
downward spiral of breathlessness. Dysfunction would be
expected to be greatest in the muscles that are least used—for
example, the locomotor muscles such as the quadriceps.
Unlike the quadriceps muscle, the abdominal muscles are not
chronically underused and are frequently recruited during
rest and exercise.5 6
This hypothesis is supported by previous studies showing
the unequal distribution of muscle weakness in COPD—in
particular, the strength of the upper extremity muscles being
relatively preserved compared with those of the lower
extremity.10 Using the non-volitional technique of supramax-
imal magnetic nerve stimulation to exclude the confounding
effects of patient motivation, we have previously shown that
both twitch adductor pollicis tension and twitch transdiaph-
ragmatic pressures are normal in patients with COPD
compared with healthy elderly controls, despite a 30%
reduction in twitch quadriceps force.2 One potential criticism
of that study is that the adductor pollicis and quadriceps
muscles vary in their fibre type distribution: the adductor
pollicis is composed principally of type I fibres (80%) whereas
the quadriceps consists of 43% type I fibres and 57% type II
fibres.3 The present study largely addresses this criticism as
the abdominal muscles have a similar fibre type distribution
to the quadriceps, comprising 46% type I fibres and 54% type
II fibres.3
Although it has been postulated that inactivity may play a
major factor in skeletal muscle dysfunction in COPD patients,
there is some evidence that this may not explain all observed
abnormalities. Maltais and colleagues have shown modifica-
tions in the myosin heavy chain profile in the vastus lateralis
of patients with COPD compared with healthy subjects
despite only modest differences in physical activity.30
Studies on emphysematous hamsters have shown reduced
oxidative capacity of their hindlimb muscles despite the
absence of a reduction in their level of activity compared with
control animals.31 Other local factors such as local exercise
induced oxidative stress may also be involved in initiating
muscle dysfunction.32
Controversy remains over whether a systemic inflamma-
tory response is a major aetiological factor in the skeletal
muscle dysfunction commonly seen in COPD. Indirect
evidence supporting this hypothesis comes from the observa-
tion that levels of tumour necrosis factor a are raised in
patients who fail to gain weight during a rehabilitation and
refeeding programme,33 while interleukin 8 levels are
inversely related to quadriceps strength in patients admitted
with an exacerbation of COPD.34 Increased levels of inter-
leukin 6 are also associated with radiological evidence of
quadriceps wasting in COPD35 and with reduced lean body
mass.36 Levels of inflammatory cytokines were not measured
in this study, and hence a systemic inflammatory process
cannot be excluded. However, the results from this study
suggest that activity protects the muscles against any
putative systemic process. Even in situations of increased
systemic inflammation such as soon after the onset of an
acute exacerbation, increased activity in the form of a
pulmonary rehabilitation programme can lead to highly
significant improvements in exercise capacity and health
status.37 Available data suggest that any future therapeutic
interventions targeted at the inflammatory process will need
to be accompanied by exercise training.
In summary, cough gastric pressures are normal in patients
with stable COPD despite the presence of significant
weakness of the quadriceps. This observation supports the
hypothesis that disuse is necessary for the development of
skeletal muscle weakness in COPD patients.
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Comparing the Pneumonia Severity Index and CURB scores
m Aujesky D, Auble TE, Yealy DM, et al. Prospective comparison of three validated prediction rules for prognosis in
community-acquired pneumonia. Am J Med 2005;118:384–92
A
number of different models have been used to assess prognosis in pneumonia. In this
study the Pneumonia Severity Index was compared with the CURB and CURB-65
severity scores in predicting 30 day mortality.
3181 patients with community acquired pneumonia were assessed between January and
December 2001 in 32 emergency departments in Connecticut and Pennsylvania. Patients
were assessed according to the criteria of the Pneumonia Severity Index, CURB, and CURB-
65 and then stratified into risk groups I–V, 0–4, and 0–5, respectively. Statistical analysis was
performed to assess 30 day mortality and the accuracy of the risk classification based on
sensitivity, specificity, likelihood ratios, and predictive values. The results indicated that the
Pneumonia Severity Index stratified more patients as low risk (68%) than CURB (51%) or
CURB-65 (61%), both p,0.001. Low risk patients identified by the Pneumonia Severity
Index had slightly lower 30 day mortality (1.4%) than those stratified as low risk in CURB
(1.7%) or CURB-65 (1.7%). It was found that the Pneumonia Severity Index had a higher
sensitivity and lower specificity than the CURB scores. All three models had high negative
predictive values (.95%).
The absolute difference in 30 day mortality based on the three models is small and of
uncertain clinical significance. However, the more complex Pneumonia Severity Index does
classify many more patients as low risk and this may have beneficial cost implications in
terms of outpatient treatment.
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